Published in Mol Cancer on March 05, 2013
MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Br J Cancer (2016) 1.39
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res (2015) 1.25
Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J (2013) 0.88
Improving cancer immunotherapy by targeting the STATe of MDSCs. Oncoimmunology (2016) 0.83
Sunitinib resistance in renal cell carcinoma. J Kidney Cancer VHL (2014) 0.82
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw (2016) 0.80
Estrogen-induced SDF-1α production promotes the progression of ER-negative breast cancer via the accumulation of MDSCs in the tumor microenvironment. Sci Rep (2016) 0.77
Novel drugs that target the metabolic reprogramming in renal cell cancer. Cancer Metab (2016) 0.76
Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther (2016) 0.75
Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients. Oncogenesis (2016) 0.75
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Blinded by the Light: The Growing Complexity of p53. Cell (2009) 17.75
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Effect of p53 status on tumor response to antiangiogenic therapy. Science (2002) 4.41
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07
Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer (2009) 4.06
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest (2010) 3.74
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol (2009) 3.41
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res (2009) 3.07
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res (2009) 2.23
Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J (2009) 2.21
Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol (2001) 2.19
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A (2005) 2.14
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
The ATM protein kinase and cellular redox signaling: beyond the DNA damage response. Trends Biochem Sci (2011) 1.91
Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell (2009) 1.82
Type IV collagen-derived angiogenesis inhibitors. Microvasc Res (2007) 1.51
p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res (2006) 1.48
The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun (2005) 1.48
p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res (2004) 1.47
Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res (2011) 1.42
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology (2009) 1.42
p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science (2006) 1.40
Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med (Berl) (2007) 1.40
Genome-wide analysis of p53 under hypoxic conditions. Mol Cell Biol (2006) 1.37
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer (2011) 1.34
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol (2008) 1.33
Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol (2005) 1.22
p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res (2010) 1.12
MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer (2010) 1.11
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One (2012) 1.08
An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer (2009) 1.05
TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer Lett (2010) 1.05
Regulation of MDMX expression by mitogenic signaling. Mol Cell Biol (2008) 1.01
Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin. Sci STKE (2006) 0.93
KR-POK interacts with p53 and represses its ability to activate transcription of p21WAF1/CDKN1A. Cancer Res (2012) 0.91
Role of transcription factors in small intestinal ischemia-reperfusion injury and tolerance induced by ischemic preconditioning. Transplant Proc (2010) 0.89
p53 inhibits angiogenesis by inducing the production of Arresten. Cancer Res (2012) 0.89
Hypoxia-inducible factor-1 and p53: friends, acquaintances, or strangers? Clin Cancer Res (2006) 0.87
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res (2010) 2.03
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res (2006) 1.65
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res (2006) 1.35
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One (2011) 1.32
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res (2007) 1.31
GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem (2007) 1.21
Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem (2003) 1.11
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther (2010) 1.10
Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res (2006) 1.06
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer (2009) 1.04
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol (2003) 1.00
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother (2009) 0.93
A novel electrochemical biosensor based on dynamic polymerase-extending hybridization for E. coli O157:H7 DNA detection. Talanta (2008) 0.92
HLA-B*1301 as a biomarker for genetic susceptibility to hypersensitivity dermatitis induced by trichloroethylene among workers in China. Environ Health Perspect (2007) 0.91
Overexpression of kinase suppressor of Ras upregulates the high-molecular-weight tropomyosin isoforms in ras-transformed NIH 3T3 fibroblasts. Mol Cell Biol (2003) 0.90
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res (2002) 0.89
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer. BJU Int (2011) 0.87
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med (2011) 0.87
A novel biomimetic olfactory-based biosensor for single olfactory sensory neuron monitoring. Biosens Bioelectron (2008) 0.85
An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood. Melanoma Res (2010) 0.85
Recent advances in olfactory receptor-based biosensors. Biosens Bioelectron (2012) 0.85
Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines. Cancer Lett (2009) 0.85
Expression and function of heme oxygenase-1 in human gastric cancer. Exp Biol Med (Maywood) (2012) 0.85
Dual inhibition of PI3-kinase and mTOR in renal cell carcinoma. Curr Cancer Drug Targets (2013) 0.85
Effects of genetic polymorphisms of N-Acetyltransferase on trichloroethylene-induced hypersensitivity dermatitis among exposed workers. Ind Health (2009) 0.85
C-type natriuretic peptide attenuates LPS-induced endothelial activation: involvement of p38, Akt, and NF-κB pathways. Amino Acids (2014) 0.84
Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods. Eur J Med Res (2013) 0.84
AlGaN/GaN heterostructures for non-invasive cell electrophysiological measurements. Biosens Bioelectron (2007) 0.84
Association between TGF-β1 polymorphisms and hepatocellular carcinoma risk: a meta-analysis. Genet Test Mol Biomarkers (2013) 0.84
Biomarkers measured by cytokinesis-block micronucleus cytome assay for evaluating genetic damages induced by polycyclic aromatic hydrocarbons. Mutat Res (2009) 0.83
Association of aryl hydrocarbon receptor gene polymorphisms and urinary 1-hydroxypyrene in polycyclic aromatic hydrocarbon-exposed workers. Cancer Epidemiol Biomarkers Prev (2008) 0.81
Assaying for BRAF V600E in tissue and blood in melanoma. Methods Mol Biol (2014) 0.80
[Nasopharyngeal and oropharyngeal airway in obstructive sleep apnea syndrome, multi-plane operation application of perioperative]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2011) 0.79
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. Mol Cancer (2011) 0.79
Biological drug duo delivers one-two tumor punch. Nat Med (2003) 0.79
An efficient vector system to modify cells genetically. PLoS One (2011) 0.78
Simple and fast fluorescence detection of benzoyl peroxide in wheat flour by N-methoxy rhodamine-6G spirolactam based on consecutive chemical reactions. Anal Chim Acta (2011) 0.77
PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells. J Cell Mol Med (2013) 0.77
A novel design of multifunctional integrated cell-based biosensors for simultaneously detecting cell acidification and extracellular potential. Biosens Bioelectron (2008) 0.77
High spatial resolution impedance measurement of EIS sensors for light addressable cell adhesion monitoring. Biosens Bioelectron (2010) 0.77
[Effect of nerve growth factor on mitochondrion dysfunction of motor neuron induced by 2,5-hexanedione]. Wei Sheng Yan Jiu (2007) 0.76
Umami evaluation in taste epithelium on microelectrode array by extracellular electrophysiological recording. Biochem Biophys Res Commun (2013) 0.76
A novel microphysiometer based on high sensitivity LAPS and microfluidic system for cellular metabolism study and rapid drug screening. Biosens Bioelectron (2012) 0.76
Immunotherapy With Low-Dose IL-2 in Combination With GM-CSF. J Immunother (2003) 0.75
Impaired erythrocyte deformability in transgenic HO-1G143H mutant mice. Transgenic Res (2014) 0.75
The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis. Clin Invest Med (2017) 0.75
Histopathological study of congenital aortic valve malformations in 32 children. Front Med China (2007) 0.75
[Development of a New Type Elastic Syndesmosis Hook Plate]. Zhongguo Yi Liao Qi Xie Za Zhi (2016) 0.75
Ionic liquid for single-drop microextraction followed by high-performance liquid chromatography-ultraviolet detection to determine carbonyl compounds in environmental waters. J Sep Sci (2010) 0.75
An olfactory bulb slice-based biosensor for multi-site extracellular recording of neural networks. Biosens Bioelectron (2011) 0.75
A novel bioelectronic nose based on brain-machine interface using implanted electrode recording in vivo in olfactory bulb. Biosens Bioelectron (2013) 0.75
The optimization of automatic fluidic system for cell-based biosensor. Conf Proc IEEE Eng Med Biol Soc (2005) 0.75
[Study on the influence factors of human peripheral blood B lymphocyte transformation by Epstein-Barr virus]. Wei Sheng Yan Jiu (2009) 0.75
Numerical design and experimental analysis of cell-based sensors. Conf Proc IEEE Eng Med Biol Soc (2005) 0.75
[The unique Entner-Doudoroff (ED) glycolysis pathway of glucose in archaea--a review]. Wei Sheng Wu Xue Bao (2008) 0.75
Zinc Nanoparticles-equipped Bioelectronic Nose Using a Microelectrode Array for Odorant Detection. Anal Sci (2016) 0.75
Genetic damage induced by organic extract of coke oven emissions on human bronchial epithelial cells. Toxicol In Vitro (2012) 0.75
Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res (2006) 0.75
[Research on motor dysfunction and the role of CTP after traumatic brain injury in rats]. Sichuan Da Xue Xue Bao Yi Xue Ban (2003) 0.75